When a YouTuber hits 500,000 subscribers, the company has found that things tend to change. That half-million milestone is something of a tipping point in terms of both growth and revenue, says ...

Mark Minevich is a NY-based strategist focused on human centric AI. The AI hype cycle is not ending, despite some mainstream opinions. Yes, the massive influx of investments and sky-high ...

Please verify your email address. YouTube is rolling out new features like Hype to boost emerging creators under 500,000 subscribers. You can only hype videos published in the last seven days ...

At the company’s Made On YouTube event on Wednesday, YouTube announced a new feature that will allow a creator’s existing viewers to help “hype” a video with a click of a button ...

In their book AI Snake Oil, two Princeton researchers pinpoint the culprits of the AI hype cycle and advocate for a more critical, holistic understanding of artificial intelligence. If you buy ...

This article evaluates the currently used treatment regimens in ocular anti-VEGF therapy for exudative age-related macular degeneration. Anti-VEGF therapies using variable injection regimens and ...

The big "We, Robot" event ended up being nothing more than a demo of robotaxi and robot prototypes. The event was held on a controlled Warner Bros. studio lot, providing a limited test of the more ...

JACKSONVILLE, Fla. -- Jaguars quarterback Trevor Lawrence is typically not an overly effusive guy. He doesn't give emotional pregame or locker room speeches. He doesn't yell at teammates or ...

The mania around Cooper Flagg at Duke is here. And it’s not going anywhere anytime soon. Flagg, the Class of 2024’s most-hyped recruit and projected 2025 No. 1 NBA Draft pick, spoke publicly ...

At the company’s Made on YouTube event on Wednesday, YouTube announced a new feature that will allow a creator’s existing viewers to help “hype” a video with a click of a button ...

The SAILOR study, the largest trial in exudative AMD to date (n = 4307), was a Phase IIIb multicenter, 1-year study evaluating a variable-dosing regimen of 3-monthly intravitreal ranibizumab (0.3 ...